This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Cell Therapeutics Announces Results From Preclinical Study Of Pixantrone (PIXUVRI®) Presented At The AACR-NCI-EORTC Meeting

SEATTLE, Oct. 21, 2013 /PRNewswire/ -- Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) today announced the presentation of findings from a preclinical study of PIXUVRI ® (pixantrone) that suggest its mechanism of inducing tumor cell death is novel and distinct from that of anthracyclines such as doxorubicin.  PIXUVRI is a first-in-class aza-anthracenedione with unique structural and physiochemical properties that is currently approved in the European Union for use as a monotherapy for the treatment of adult patients with multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma.  The study results were presented by Neil Beeharry, Ph.D., at the Fox Chase Cancer Center during a poster session at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics held October 19-23, 2013 in Boston, MA. 

"The study results suggest that PIXUVRI is unique in its mechanism for inducing tumor cell death, thereby supporting the thesis that it is the first approved drug in a new class of anti-cancer agents.  PIXUVRI's mechanism of action is differentiated from the cytotoxic action induced by anthracyclines and could be the basis for the efficacy and safety profile of the drug," stated Dr. Beeharry.

The study assessed the mechanism of tumor cell killing induced by PIXUVRI in a variety of cancer cell lines.  Specifically, the study assessed the impact PIXUVRI had on cell proliferation and time to cell death, the cell cycle, DNA damage response and longer term effects on cell division.  Unlike anthracyclines -- which kill both normal and cancer cells with short-term exposure -- PIXUVRI had minimal short-term effects on cell survival, but probably through formation of stable DNA adducts, caused delayed but efficient tumor cell death.  This effect was not dependent on the presence of the p53 gene, a gene associated with recognition of chromosomal damage and apoptosis.  Loss of p53 was only associated with a further delay in cell death with longer exposure to PIXUVRI.  The authors concluded that PIXUVRI appears to be impairing chromosomal segregation during mitosis, thereby generating loss of genetic material in daughter cells, an abnormality, which is ultimately lethal, and that PIXUVRI would likely be effective in cells resistant to other cytotoxic agents such as doxorubicin.  The authors are pursuing leads to further understand the exact mechanism of action.

1 of 3

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,279.74 +13.75 0.08%
S&P 500 2,010.40 -0.96 -0.05%
NASDAQ 4,579.7890 -13.6380 -0.30%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs